Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Otsuka To Buy U.S. Start-Up Astex Pharmaceuticals
http://e.nikkei.com/e/fr/freetop.aspx
No.
$RMTI hope to see this one fly today.
Rockwell Medical Announces SFP Meets Primary and Key Secondary Endpoints in Phase 3 CRUISE-2 Efficacy Study as a Treatment for Iron Replacement in Chronic Kidney Disease Patients on Dialysis
In Dialysis Patients Not Receiving IV Iron, SFP Effectively Delivers Iron via Dialysate and Maintains Hemoglobin Without Increasing Stored Iron (Ferritin); Strong Safety Data Demonstrates No Anaphylactic Events and No Increase in Hypotension or Infection; Consistent, Positive Results Achieved Across Two Phase 3 Efficacy Studies; Conference Call to Be Held Today, Wednesday September
http://yhoo.it/14XXtKo
CVac(TM) CAN-003 Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer Annual Meeting
SYDNEY, AUSTRALIA--(Marketwired - Sep 3, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN:US74154B2034) ("Prima", the "Company") today announced that the abstract entitled, "Study of Autologous Dendritic Cell Therapy Targeting Mucin 1 as a Treatment for the Maintenance of Ovarian Cancer Patients in Remission" has been accepted for a poster presentation at the Society for Immunotherapy of Cancer ("SITC") 28th Annual Meeting. Further analyses of clinical and immunological data from the CAN-003 clinical trial of CVacâ„¢ will be presented.
The poster will be presented by Prima's Chief Technical Officer, Dr. Sharron Gargosky, at the Gaylord National Hotel and Convention Center in National Harbor, MD. Poster presentations are scheduled to occur on Friday, November 8, 2013 from 12:30 p.m. - 2:00 p.m. and on Saturday, November 9, 2013 from 12:30 p.m. - 2:00 p.m. The exact time and location of Dr. Gargosky's poster presentation will be available closer to the conference date.
Dr. Goh, the CAN-003 study team, Dr. Gargosky, and Dr. Heidi Gray are the authors of the abstract. CAN-003 is a 63-patient phase 2 study evaluating the effect of CVac on progression free and overall survival, as well as safety and immune responses, in patients in remission after first line treatment for epithelial ovarian cancer. As previously announced by Prima, topline data from the CAN-003 will be presented by Dr. Jeffrey Goh at the European Cancer Congress on October 1, 2013 in Amsterdam.
http://yhoo.it/19hN5Nf
Rockwell Medical to Discuss Top-Line Results From Final SFP Phase 3 Efficacy Study CRUISE-2
Conference Call Wednesday, September 4, 2013 at 8:30am EDT
WIXOM, MI--(Marketwired - Sep 3, 2013) - Rockwell Medical (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, will host a conference call tomorrow, Wednesday, September 4th at 8:30am EDT to review top-line results from their Phase 3 (CRUISE-2) efficacy study of SFP, the Company's late-stage investigational iron-delivery drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis. Rockwell will announce the top-line results tomorrow morning prior to the call.
On the call from Rockwell will be Rob Chioini, Founder, Chairman and Chief Executive Officer, Dr. Raymond Pratt, Chief Medical Officer, and Dr. Ajay Gupta, Chief Scientific Officer.
To participate in the conference call, please call 1-877-383-7438 (U.S.), 1-678-894-3975 (outside the U.S.), call-in ID: 49150189. The call will be webcast simultaneously at http://ir.rockwellmed.com/events.cfm and will be available for replay at this link for 14 days.
http://yhoo.it/13aOEf3
$heff I followed you in on $NVAX, I was already in $AMRN. Thx.
Thanks $heff.
$PBMD 2.30 files $60 mil shelf.
PRIMA BIOMED FILES U.S. SHELF REGISTRATION STATEMENT
Prima BioMed Ltd ABN 90 009 237 889 (Company or Prima BioMed) advisesthat it has
filed a shelf registration statement on Form F-3 with the U.S. Securities and Exchange
Commission (SEC).
When effective, the registration statement would allow the Company to issue, over a period
of three years from time to time, up to a total of US$60 million worth of ordinary fully paid
shares in the Company (which will trade in the United States in the form of American
depository shares (ADS)).
Shelf registrations are common practice in the United States as they allow a company to
complete the usually extensive SEC review process prior to the issuing of any securities and
then have up to three years within which to use the prospectus.
The registration statement relating to these potential future issues has been filed with the
SEC, but has not yet become effective. These securities may not be sold nor may offers to
buy be accepted prior to the time the registration statement becomes effective. This
announcement shall not construe an offer to sell or a solicitation of an offer to buy nor shall
there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the securities laws of any such
jurisdiction. Any offering of these securities shall be made only by means of a prospectus
contained in the registration statement filed with and declared effective by the SEC.
The terms and price of any future potential offering would be established at that time.
ADS currently trade on the NASDAQ Global Market under the code PRMD and each ADS
represents 30 ordinary shares in the Company.
http://bit.ly/1dT48c6
$RPTP 12.04 bought on the dip premarket @ 11.48
Alimera, pSivida Eye Drug Warrants FDA Approval On Third Try
http://bit.ly/1dmFMZu
Astex Pharmaceuticals Announces Topline Results of SGI-110 AML Phase 2 Study
DUBLIN, Calif., Aug. 28, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (ASTX) today announced topline results from the ongoing phase 2 of SGI-110 in patients with AML and MDS. The Phase 2 study is a randomized study of SGI-110 given either as 60 or 90 mg/m2 daily for 5 days in a 28-day course. As of end of June data cutoff, 67 AML patients had a minimum follow up of 3 months (50 patients representing the complete cohort of relapsed/refractory AML, and 17 patients in the treatment-naive elderly AML not suitable for induction chemotherapy cohort). The primary endpoint is overall remission rate (Complete Remission or CR; Complete Remission with Incomplete hematologic recovery or CRi/CRp). There were 8 remissions in relapsed/refractory AML and 9 remissions in treatment-naive elderly AML for an overall complete remission rate (CR, CRi/CRp) of 17/67 or 25%. The detailed results have been submitted for presentation to the American Society of Hematology (ASH) meeting to be held later this year during December 7-10 in New Orleans, LA.
http://yhoo.it/16PEJss
$AMRN still has the AdCom coming.
He forgot to mention that today the USPTO officially gave Epanova the THUMBS DOWN and rejected all patent coverage, mainly bc of Vascepa's patent protection.. Therefore, Eponova may either not be approved or if approved have zero patent coverage. AZN just wasted $260 mill...
Where's the link for this??
OT: according to my broker(Schwab) the $NASDAQ market will reopen at 3:05. Execution reports will be delayed by 5 minutes.
Link to $NASDAQ halt.
http://bit.ly/1bXqsPL
Link to $NASDAQ halt.
http://bit.ly/1bXqsPL
Temporary halt on all NASDAQ traded stocks.
Temporary halt on all NASDAQ traded stocks.
HAHAHAHAHA
$HALO Top Buys by Directors: Falberg's $681.6K Bet on HALO
The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company would choose to take their hard-earned cash and use it to buy stock in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both. So in this series we look at the largest insider buys by company directors over the trailing six month period, one of which was a total of $681.6K by Kathryn E. Falberg, Director at Halozyme Therapeutics Inc (NASD: HALO).
http://onforb.es/19l7O3r
apparently not.
Who knows, hopefully up.
Jason Napodano, CFA ?@JNapodano
$ASTM now talking about NASDAQ min-bid. They will seek shareholder approval for permission to effect a reverse split. Vote in November 2013.
Jason Napodano, CFA ?@JNapodano
$ASTM offering (to close tomorrow) was limited b/c they hit their maximum authorized share count. Will ask shlds to vote on increase soon.
Overall bad market day.
Gotcha.....
$heff are you buying more $PBMD while its down this low?
$HPTX earnings after market close.
I have to agree. $AMRN management really blew it so far.
T2M with you on that one. Sold 1/2 @ 1.56. the rest can ride and will add on any pullbacks.
$ZLCS its on the very bottom.
$ZLCS Top Projects to Watch
The Top Projects to Watch are chosen to present in each therapeutic area, and are hand-picked by a panel of independent experts who screen hundreds of compounds and weigh their potential as future products. Many presenting companies in previous years have gone on to establish major partnerships. http://bit.ly/1bmxP32
That is excellent news. Thanks for letting us know $heff.
$heff my prayers are with these two young girls. I hope they recover, soon.
$CYTK Or info has leaked and it's not good info. It happens...
Avg. daily volume is 1,247,100. It's well below that right now, looks like a shakeout. JMO